ARTG Entry
CAELYX
ARTG entry for CAELYX (doxorubicin hydrochloride), ARTG 79921 — Product Information, dosage form, registration history. Compiled by arcimedes.
- Sponsor: Baxter Healthcare
- Active ingredient: doxorubicin hydrochloride
- Therapeutic area: Oncology
What it is
CAELYX is a doxorubicin hydrochloride concentrated injection available in two strengths: 20 mg/10 mL and 50 mg/25 mL vials.
Regulatory history
CAELYX doxorubicin hydrochloride 20 mg/10 mL was first registered on the ARTG on 6 August 1997. The 50 mg/25 mL strength was added to the ARTG on 6 December 2001.